CC312
Phase 1Biologic
CC312 is one of 40 biologic programs targeting Autoimmune Disease. It is currently in Phase 1.
1
Indications
4
Total Trials
4
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Autoimmune Disease
#DrugCompanyPhaseTrials
1Myfortic
NovartisPhase 3
Remicade
OOrganon and Co
Phase 3
Atgam
NovartisPhase 2
Blincyto
AmgenPhase 2
Cytosar
TevaPhase 2
Soliris
AstraZenecaPhase 2
Rayos
RRoxane Laboratories
Phase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
Alkeran
AApotex Inc.
Phase 2
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autoimmune Disease2 trials
Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CC312. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCytoCares Inc